Bobak Azamian, Tarsus CEO
July 25, 2023 11:23 AM EDT
Pharma
FDA+

Tar­sus scores first FDA ap­proval for treat­ment of red, itchy eyes caused by mites

Nicole DeFeudis

Editor

Tar­sus Phar­ma­ceu­ti­cals has se­cured the FDA’s first ap­proval to treat ir­ri­tat­ed eyes caused by tiny mites, a con­di­tion known as de­mod­ex …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times